Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer with Mediastinal Lymph Node Involvement

Research output: Contribution to journalReview article

25 Scopus citations

Abstract

Survival outcomes of patients with stage IIIA non-small cell lung cancer (NSCLC) with mediastinal lymph node involvement (N2 disease) have been poor when treated with surgery alone. Numerous studies have investigated induction chemotherapy, radiation, and chemoradiation to attempt to improve outcome in this high-risk population. The appropriate application and sequence of these treatments is still the subject of ongoing study. Surgical resection appears to have the greatest benefit in patients who have decreased mediastinal involvement following induction therapy, although the type of surgical resection (pneumonectomy or lesser resection) impacts morbidity and mortality risks after induction therapy. Molecularly targeted agents are also being studied as a potential induction therapy for use in the treatment of stage IIIA disease.

Original languageEnglish (US)
Pages (from-to)403-415
Number of pages13
JournalThoracic Surgery Clinics
Volume18
Issue number4
DOIs
StatePublished - Nov 1 2008

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer with Mediastinal Lymph Node Involvement'. Together they form a unique fingerprint.

  • Cite this